Outset Medical earnings date
Want to see OM full AI Analyst Report?
Outset Medical (OM) Q3 2026 Earnings Report
OM Q3 2026 EPS Results
- Actual EPS
- -$0.68
- Consensus EPS
- -$0.69
- Beat/Miss
- Beat by +$0.01
- One Year Ago EPS
- -$0.69
OM Q3 2026 Revenue Results
- Actual Revenue
- $33.60M
- Expected Revenue
- $31.40M
- Beat/Miss
- Beat by +$2.20M
- YoY Revenue Growth
- +14.15%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- After Close
- Conference Call
- Wednesday, November 4, 2026
Outset Medical's next earnings date is estimated for February 17, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was predominantly positive, with 14% year-over-year revenue growth, 26% console revenue growth, improved company-wide gross margin, more than 300 basis points of operating leverage, strong customer satisfaction and retention, and substantial refresh and expansion opportunities. The main negatives were the year-over-year increase in non-GAAP net loss, a 150-basis-point decline in product gross margin, ongoing cash use, and the fact that the next-generation system and HHS policy benefits remain subject to future execution and implementation.
Outset reiterated full year revenue guidance of $125 million to $130 million for 2026 and continues to expect full year non-GAAP gross margin to be in the low 40% to mid-40% range, with a higher mix of console sales potentially shifting gross margin towards the lower end of that range; the company is also on track to use approximately $40 million for the full year, toward its next milestone of a 50% company-wide gross margin, and said it wants to return to a double-digit growth company, with further 2027 detail expected when it reports Q4.
- Revenue Growth Across All Revenue LinesThird-quarter revenue was $33.6 million, up 14% year-over-year and 6% sequentially. Each revenue line item contributed to both year-over-year and sequential growth.
- Console and Recurring Revenue ExpansionConsole revenue was $10.5 million, up 26% year-over-year, driven by new and refreshed console sales. Product revenue was $23.7 million, up 15%; consumable revenue was $13.2 million, up 8%; service and other revenue was $9.9 million, up 12%; and recurring revenue was $23.1 million, up 10%. EMR offering sales grew 23% year-over-year.
- Improved Company-Wide Gross MarginThird-quarter non-GAAP gross margin was 40.8%, up approximately 100 basis points year-over-year, driven primarily by product cost improvements, reduced overhead and service efficiencies. Management said the company remains on track toward its next milestone of a 50% company-wide gross margin.
- Significant Operating LeverageThe company delivered over 300 basis points of operating leverage. Non-GAAP operating expenses were $24.2 million and, excluding approximately $1 million related to bad debt expense, increased only 4% compared with 14% revenue growth.
- Strong Customer Implementation ActivityThe clinical excellence team completed new go-live implementations for new customers and existing customers expanding to new locations, including four of the top 10 U.S. health systems.
- Customer Satisfaction Exceeded Healthcare BenchmarksIn a third-party voice-of-the-customer assessment, Outset's overall customer satisfaction score exceeded all of the consulting firm's healthcare benchmarks. Customers scored Tablo highly for timely dialysis, improved patient satisfaction, lower infrastructure burden and system costs, and simpler dialysis delivery.
- High Customer RetentionCumulative retention among parent customers that have purchased Tablo consoles has been 96% since commercial launch. Management attributed this to the technology and the broader customer experience across field service, clinical excellence, data analytics, EMR and other functions.
- Refresh Opportunity and HCA AgreementThe first significant refresh agreement, signed with HCA in the second quarter, added contracted backlog and revenue visibility and validated the refresh opportunity. Management cited an estimated $150 million refresh opportunity representing more than 3,000 consoles over the next several years.
- Expansion Opportunity Across Large Health SystemsAll 14 of the largest health systems by estimated console opportunity are already Outset customers, and Tablo is used in one or more facilities of roughly half of the top 100 largest IDNs. The company closed third-quarter deals involving both same-store expansion and expansion into new facilities.
- Commercial Organization InvestmentsOutset is reducing territory sizes to help representatives build deeper relationships, realigning compensation incentives around commercial priorities, expanding the capital sales team regionally and at the national-account level, and focusing on the nation's top 250 health systems.
- Positive Home Dialysis MetricsAs the home business and patient census have grown, Outset has maintained an industry-leading retention rate of 90% or greater during the first 90 days. Management also said Tablo continues to lead the industry in how quickly and easily patients and caregivers can be trained for home use.
- Potential Policy Tailwind for Dialysis AdoptionManagement viewed the Department of Health and Human Services' Kidney Care National Plan as a positive potential development because it emphasizes patient choice, expanded home dialysis, new dialysis technologies, reduced barriers for new dialysis service entrants and broader treatment options.
- Reiterated 2026 Revenue GuidanceThe company reiterated full-year 2026 revenue guidance of $125 million to $130 million and expects full-year non-GAAP gross margin to be in the low 40% to mid-40% range. Management cited a strong commercial pipeline and contracted backlog related to the HCA refresh agreement as support for the outlook.
- Progress Toward Next-Generation TabloOutset is advancing preparations for next-generation Tablo and is prioritizing a high-quality customer experience before a full release. Management said it looks forward to seeing the system in the market at scale in the coming months and quarters.
- Record Cumulative Treatment BaseCustomers have generated 4 million cumulative dialysis treatments with Tablo, which management cited as evidence of the measurable value created for customers and patients.
OM Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 17, 2027 | 2026 (Q4) | -0.66- | -0.84 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | -0.69-0.68 | -0.69 | 1.45% (+0.01) | |
| Aug 06, 2026 | 2026 (Q2) | -0.72-0.80 | -0.84 | 4.76% (+0.04) | |
| May 07, 2026 | 2026 (Q1) | -0.79-0.83 | -3.24 | 74.38% (+2.41) | |
| Feb 11, 2026 | 2025 (Q4) | -0.67-0.84 | -5.55 | 84.86% (+4.71) | |
| Nov 10, 2025 | 2025 (Q3) | -0.66-0.69 | -5.85 | 88.21% (+5.16) | |
| Aug 06, 2025 | 2025 (Q2) | -0.98-0.84 | -7.05 | 88.09% (+6.21) | |
| May 07, 2025 | 2025 (Q1) | -0.94-3.24 | -8.55 | 62.11% (+5.31) | |
| Feb 19, 2025 | 2024 (Q4) | -6.20-5.55 | -8.85 | 37.29% (+3.30) | |
| Nov 06, 2024 | 2024 (Q3) | -6.60-5.85 | -10.65 | 45.07% (+4.80) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

